Literature DB >> 30093698

Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis.

Margo D M Faay1, Pál Czobor2, Iris E C Sommer3,4.   

Abstract

As violence against self and others is an important outcome in the treatment of patients with psychosis-spectrum disorders and hostility is an important indicator for violence, we set out to evaluate the effects of different types of antipsychotic agents in reducing hostility. We performed a systematic literature search, which provided 18 suitable randomized studies comparing typical to atypical antipsychotics for at least 4 weeks in patients with psychotic disorders. Results showed a small (0.26) but significant effect for atypical as compared to typical antipsychotics, with high heterogeneity, even though the mean dose of typical antipsychotics was higher. This effect size remained similar when separately analyzing sponsored and non-sponsored studies. When differentiating between high and low-dose studies, the high-dose group showed a significant difference between typical and atypical antipsychotics whereas the low-dose group did not. An analysis comparing clozapine to typical antipsychotics showed a moderate effect size (0.415), with low heterogeneity. These results are important for clinicians to help their shared decision making with patients when choosing maintenance treatment, as next to efficacy for psychosis and tolerability, safety for the patient and their environment is an important outcome.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30093698      PMCID: PMC6180076          DOI: 10.1038/s41386-018-0161-2

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  48 in total

Review 1.  Violent behaviour among people with schizophrenia: a framework for investigations of causes, and effective treatment, and prevention.

Authors:  Sheilagh Hodgins
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-08-12       Impact factor: 6.237

2.  Basics of meta-analysis: I2 is not an absolute measure of heterogeneity.

Authors:  Michael Borenstein; Julian P T Higgins; Larry V Hedges; Hannah R Rothstein
Journal:  Res Synth Methods       Date:  2017-01-06       Impact factor: 5.273

3.  Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.

Authors:  B J Kinon; S M Roychowdhury; D R Milton; A L Hill
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

4.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 5.  Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting.

Authors:  Christoph U Correll; Xin Yu; Yutao Xiang; John M Kane; Prakash Masand
Journal:  Ann Clin Psychiatry       Date:  2017-05       Impact factor: 1.567

6.  Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.

Authors:  Leslie Citrome; Jan Volavka; Pal Czobor; Shlomo Brook; Antony Loebel; Francine S Mandel
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 7.  Psychopharmacological treatment of aggression in schizophrenic patients.

Authors:  T Brieden; M Ujeyl; D Naber
Journal:  Pharmacopsychiatry       Date:  2002-05       Impact factor: 5.788

8.  Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.

Authors:  Jan Volavka; Pal Czobor; Karen Nolan; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Jeffrey A Lieberman
Journal:  J Clin Psychopharmacol       Date:  2004-04       Impact factor: 3.153

9.  Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.

Authors:  A Breier; R W Buchanan; B Kirkpatrick; O R Davis; D Irish; A Summerfelt; W T Carpenter
Journal:  Am J Psychiatry       Date:  1994-01       Impact factor: 18.112

10.  Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.

Authors:  A Delcker; M L Schoon; B Oczkowski; H J Gaertner
Journal:  Pharmacopsychiatry       Date:  1990-05       Impact factor: 5.788

View more
  2 in total

Review 1.  Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.

Authors:  Ana Miruna Dragoi; Ioana Radulescu; Bogdana Adriana Năsui; Anca Lucia Pop; Valentin Nicolae Varlas; Simona Trifu
Journal:  Brain Sci       Date:  2020-11-11

Review 2.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Authors:  Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas
Journal:  Psychother Psychosom       Date:  2020-04-14       Impact factor: 17.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.